Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 28.

Grimm, O; Kraehenmann, R; Preller, K H; Seifritz, E; Vollenweider, F X (2018). Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. European Neuropsychopharmacology, 28(6):691-700.

Kometer, Michael; Vollenweider, Franz X (2016). Serotonergic hallucinogen-induced visual perceptual alterations. In: Kometer, Michael; Vollenweider, F X. Current Topics in Behavioral Neurosciences. Springer-Verlag Berlin Heidelberg 2016: Springer, 1-26.

Preller, Katrin H; Ingold, Nina; Hulka, Lea M; Vonmoos, Matthias; Jenni, Daniela; Baumgartner, M R; Vollenweider, F X; Quednow, Boris B (2013). Increased sensorimotor gating in recreational and dependent cocaine users is modulated by craving and attention-deficit/hyperactivity disorder symptoms. Biological Psychiatry, 73(3):225-234.

Studerus, E; Gamma, A; Kometer, M; Vollenweider, F X (2012). Prediction of psilocybin response in healthy volunteers. PLoS ONE, 7(2):e30800.

Quednow, Boris B; Treyer, V; Hasler, F; Dörig, N; Wyss, M T; Burger, C; Rentsch, K M; Westera, G; Schubiger, P A; Buck, A; Vollenweider, F X (2012). Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [(18)F]altanserin positron emission tomography. NeuroImage, 59(4):3922-3932.

Schmidt, A; Bachmann, R; Kometer, M; Csomor, P A; Stephan, K E; Seifritz, E; Vollenweider, F X (2012). Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments. Neuropsychopharmacology, 37(4):865-875.

Quednow, Boris B; Kometer, M; Geyer, M A; Vollenweider, F X (2012). Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology, 37(3):630-640.

Studerus, E; Kometer, M; Hasler, F; Vollenweider, F X (2011). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. Journal of Psychopharmacology, 25(11):1434-1452.

Kometer, M; Cahn, B R; Andel, D; Carter, O L; Vollenweider, F X (2011). The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations. Biological Psychiatry, 69(5):399-406.

Studerus, E; Gamma, A; Vollenweider, F X (2010). Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS ONE, 5(8):e12412.

Hysek, C M; Vollenweider, F X; Liechti, M E (2010). Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy). Emergency Medicine Journal (EMJ), 27(8):586-589.

Holstein, D H; Vollenweider, F X; Jäncke, Lutz; Schopper, C; Csomor, P A (2010). P50 suppression, prepulse inhibition, and startle reactivity in the same patient cohort suffering from posttraumatic stress disorder. Journal of Affective Disorders, 126(1-2):188-197.

Roser, P; Vollenweider, F X; Kawohl, W (2010). Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists. World Journal of Biological Psychiatry, 11(2 Pt 2):208-219.

Hilti, C C; Delko, T; Orosz, A T; Thomann, K; Ludewig, S; Geyer, M A; Vollenweider, F X; Feldon, J; Cattapan-Ludewig, K (2010). Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naïve first-episode schizophrenia patients. Neuropsychobiology, 61(2):79-86.

Vollenweider, F X; Kometer, M (2010). The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nature Reviews. Neuroscience, 11(9):642-651.

Hasler, F; Studerus, E; Lindner, K; Ludewig, S; Vollenweider, F X (2009). Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA. Journal of Psychopharmacology, 23(8):923-935.

Quednow, Boris B; Schmechtig, A; Ettinger, U; Petrovsky, N; Collier, D A; Vollenweider, F X; Wagner, M; Kumari, V (2009). Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study. Biological Psychiatry, 66(6):614-620.

Hasler, F; Kuznetsova, O F; Krasikova, R N; Cservenyak, T; Quednow, Boris B; Vollenweider, F X; Ametamey, S M; Westera, G (2009). GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies. Applied Radiation and Isotopes, 67(4):598-601.

Csomor, P A; Yee, B K; Feldon, J; Theodoridou, A; Studerus, E; Vollenweider, F X (2009). Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients. Schizophrenia Bulletin, 35(1):244-255.

Geyer, M A; Vollenweider, F X (2008). Serotonin research: contributions to understanding psychoses. Trends in Pharmacological Sciences, 29(9):445-453.

Csomor, P A; Yee, B K; Vollenweider, F X; Feldon, J; Nicolet, T; Quednow, Boris B (2008). On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behavioral Neuroscience, 122(4):885-900.

Quednow, Boris B; Csomor, P A; Chmiel, J; Beck, T; Vollenweider, F X (2008). Sensorimotor gating and attentional set-shifting are improved by the μ-opioid receptor agonist morphine in healthy human volunteers. International Journal of Neuropsychopharmacology, 11:655-669.

Wackermann, J; Wittmann, M; Hasler, F; Vollenweider, F X (2008). Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neuroscience Letters, 435(1):51-55.

Cattapan-Ludewig, K; Ludewig, S; Messerli, N; Vollenweider, F X; Seitz, A; Feldon, J; Paulus, M P (2008). Decision-making dysregulation in first-episode schizophrenia. Journal of Nervous and Mental Disease, 196(2):157-160.

Csomor, P A; Stadler, R R; Feldon, J; Yee, B K; Geyer, M A; Vollenweider, F X (2008). Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels. Neuropsychopharmacology, 33(3):497-512.

Vollenweider, F X (2008). Multidimensional approach to sensory gating functions and cognition in humans. In: Gustafson, R; Eberhard, J. The diagnostic concept of schizophrenia: via the laboratory to the clinic: report based on a conference held in Zurich, Switzerland 6th-7th December 2007. Stockholm: H. Lundbeck AB, 33-44.

Vollenweider, F X (2008). Struktur und Neurobiologie der Halluzinogenerfahrung. In: Jungaberle, H; Gasser, P; Weinhold, J; Verres, V. Therapie mit psychoaktiven Substanzen. Bern: Hans Huber, 111-130.

Umbricht, D; Vollenweider, F X; Schmid, L; Grübel, C; Skrabo, A; Huber, T; Koller, R (2003). Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia. Neuropsychopharmacology, 28(1):170-181.

This list was generated on Sat Jun 15 22:29:07 2019 CEST.